Clinical Trials Browser

Phase 2 × Completed × Bevacizumab × Clear all

NCT02350530 2026-05-22

FORBES

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02308527 2026-05-12

BEACON

Phase 2 Completed

Neuroblastoma

NCT04042558 2026-05-12

GFPC 06-2018

Phase 2 Completed

150 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Phase 2 Completed

19 enrolled 10 charts

DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT03818061 2026-04-24

ATHENA

Phase 2 Completed

Head and Neck Neoplasms

NCT05625893 2026-04-23

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04147351 2026-04-21

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Phase 2 Completed

NSCLC Stage IIIB~IV

NCT03694262 2026-04-13

EndoBARR

Phase 2 Completed

30 enrolled 7 charts

Endometrial Neoplasms

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

Meningeal Carcinomatosis

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT01303497 2026-03-13

ANGIO-TAX+

Phase 2 Completed

Hemangiosarcoma

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT00826540 2026-01-20

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

83 enrolled 10 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

169 enrolled 14 charts

Melanoma

NCT03532295 2025-11-21

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2 Completed

51 enrolled 16 charts

Glioblastoma, Glioma

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Ovarian Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

Phase 2 Completed

35 enrolled 17 charts

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

NCT05480306 2025-08-03

DeFianCe

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2 Completed

105 enrolled 29 charts

Ovarian Neoplasms

NCT03890952 2025-07-24

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Phase 2 Completed

Brain Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

Ovarian Neoplasms

NCT02138617 2025-05-18

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Phase 2 Completed

100 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT05750030 2025-05-06

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2 Completed

38 enrolled 12 charts

Endometrial Neoplasms

NCT04705519 2025-03-14

Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT04072198 2025-03-13

NIVACOR

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT03396926 2025-02-28

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Phase 2 Completed

44 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT04997382 2025-02-25

CLASSIC5

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Phase 2 Completed

83 enrolled 17 charts

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT01894061 2025-02-17

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Phase 2 Completed

25 enrolled 16 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02724878 2025-02-13

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2 Completed

65 enrolled 30 charts

Kidney Neoplasms

NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Phase 2 Completed

35 enrolled 13 charts

GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT05593328 2025-01-10

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Phase 2 Completed

Ovarian Cancer Recurrent

NCT00410956 2024-12-10

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Phase 2 Completed

22 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00309998 2024-10-29

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04091217 2024-10-24

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase 2 Completed

43 enrolled 12 charts

Melanoma

NCT02096354 2024-10-15

ROCKET

Phase 2 Completed

62 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms